Premium
Abnormal liver transaminases and conjugated hyperbilirubinemia at presentation of acute lymphoblastic leukemia
Author(s) -
Segal Idit,
Rassekh S. Rod,
Bond Mason C.,
Senger Christof,
Schreiber Richard A.
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22549
Subject(s) - medicine , elevated transaminases , gastroenterology , chemotherapy , jaundice , leukemia , malignancy , hepatitis , alanine transaminase , pediatrics , methotrexate
Background Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood. While hepatitis is a well‐known complication during the treatment phase of ALL, the association of abnormal liver biochemistries at initial presentation of leukemia is poorly described. The aim of this study is to examine the prevalence and assess the clinical impact of hepatitis at diagnosis in children with ALL. Procedure All children diagnosed with ALL at BC Children's Hospital between 2001and 2006 were included. Charts were reviewed and data recorded to a computerized spreadsheet. Descriptive statistical analyses were performed. Results One hundred forty‐seven ALL patients were identified. Over one third of patients had abnormal liver transaminase values (AST and/or ALT). Of the patients with abnormal transaminases, (52%) had ALT elevations twice the upper limit of normal. Risk factors for elevated transaminases included a high WBC count at diagnosis, older age, bulky disease, and T‐cell leukemia. Conjugated hyperbilirubinemia was observed in 3.4% of subjects. Of these cases, 60% received steroids prior to induction chemotherapy and all had rapid resolution of their hyperbilirubinemia to normal levels. Conclusions Elevated transaminases are common at initial presentation of ALL and are likely due to hepatic injury from leukemic infiltrates. Conjugated hyperbilirubinemia at presentation may require treatment modification and dose reduction. A short course of steroids prior to initiation of induction chemotherapy appears to result in rapid resolution of the hyperbilirubinemia with subsequent ability to provide full dosing of induction chemotherapy. Pediatr Blood Cancer. 2010;55:434–439. © 2010 Wiley‐Liss, Inc.